Navigation Links
BioCis Pharma Starts Phase IIa Trial in Psoriasis

TURKU, Finland, March 12 /PRNewswire/ -- BioCis Pharma Ltd., a privately-held drug development company with its headquarters in Turku, Finland, announced that it has begun a new Phase IIa clinical testing of ProtoCure(TM) emulsion cream, the company's novel topical drug for dermatology. The double-blind, vehicle-controlled study is designed to evaluate the tolerability, pharmacokinetics, and efficacy of the topical product in a total of 18 subjects with mild to moderate plaque psoriasis. The subjects will apply ProtoCure(TM) emulsion cream up to four weeks to the skin areas affected by the disease.

"With the commencement of this clinical trial we expand our clinical activities to a new dermatological indication," says Lasse Leino, CEO of BioCis Pharma. "Together with the ongoing phase IIa clinical trial in patients with mild to moderate atopic dermatitis, this first study in psoriasis will quickly enable us to obtain data to support our full-scale phase II clinical development program of ProtoCure(TM) emulsion cream in chronic skin inflammation. We expect to get results from both studies by third quarter of 2009."

Psoriasis is an immune-mediated chronic inflammatory disease characterized by local lesions on the skin. It affects about 2 to 3 per cent of the general population in the Western countries. Psoriasis may significantly impair the life quality of the affected subjects, and it may lead to psoriatic arthritis, an inflammatory disease affecting the joints. Existing treatments often have undesirable side effects and do not always meet the needs of patients.

BioCis Pharma Ltd is an innovative drug development company with a business idea to develop drug therapies based on a novel, patented therapeutic principle. BioCis Pharma is targeting unmet medical needs in substantial therapeutic markets including inflammation, allergy, and cancer. The company's main investors are Karolinska Development AB (publ.), Finnish Industry Investment Ltd., and Etra Invest Ltd.

Contacts: Dr. Lasse Leino, CEO, BioCis Pharma Ltd. mobile phone +358-40-849-4694,

SOURCE BioCis Pharma Ltd
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Helix BioPharma Form 20-F Registration Statement Declared Effective by SEC
2. Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2008 Results
3. Advance Nanotechs Owlstone Announces First Pharmaceutical Industry Order
4. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2008 Financial Results on Friday, March 13, 2009 at 8:30am EDT
5. XTL Biopharmaceuticals Ltd. Extraordinary General Meetings Postponed Until March 18, 2009
6. SCOLR Pharma, Inc. Reports Fourth Quarter 2008 Financial Results
7. Pharmaxis Appoints French Distributor for Aridol(TM)
8. Poniard Pharmaceuticals Reschedules Fourth Quarter and Fiscal 2008 Results Conference Call for Monday, March 16
9. Onyx Pharmaceuticals to Present at the Cowen and Company 29th Annual Health Care Conference
10. R&D Spending by U.S. Biopharmaceutical Companies Increases 3 Percent in 2008
11. Amylin Pharmaceuticals to Present at Cowen and Company Annual Health Care Conference
Post Your Comments:
(Date:10/11/2017)... ... October 11, 2017 , ... ... has granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer and ... of osteosarcoma. SBT-100 is able to cross the cell membrane and bind intracellular ...
(Date:10/10/2017)... California (PRWEB) , ... October 10, 2017 , ... Dr. ... speaking at his local San Diego Rotary Club. The event entitled ... Diego, CA and had 300+ attendees. Dr. Harman, DVM, MPVM was joined by ...
(Date:10/10/2017)... ... 2017 , ... The Pittcon Program Committee is pleased to ... who have made outstanding contributions to analytical chemistry and applied spectroscopy. Each award ... conference and exposition for laboratory science, which will be held February 26-March 1, ...
(Date:10/9/2017)... ... October 09, 2017 , ... The Giving Tree Wellness Center ... the needs of consumers who are incorporating medical marijuana into their wellness and ... , As operators of two successful Valley dispensaries, The Giving Tree’s two founders, ...
Breaking Biology Technology:
(Date:4/11/2017)... 2017 No two people are believed ... New York University Tandon School of Engineering and ... that partial similarities between prints are common enough ... phones and other electronic devices can be more ... lies in the fact that fingerprint-based authentication systems ...
(Date:4/5/2017)... 2017  The Allen Institute for Cell Science today ... one-of-a-kind portal and dynamic digital window into the human ... first application of deep learning to create predictive models ... and a growing suite of powerful tools. The Allen ... future publicly available resources created and shared by the ...
(Date:4/4/2017)... , April 4, 2017   EyeLock LLC , ... that the United States Patent and Trademark Office (USPTO) ... covers the linking of an iris image with a ... and represents the company,s 45 th issued patent. ... is very timely given the multi-modal biometric capabilities that ...
Breaking Biology News(10 mins):